Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma

A coordinated action of innate and adaptive immune responses is required to efficiently combat a microbial infection. It has now become clear that cancer therapies also largely benefit when both arms of the immune response are engaged. In this review, we will briefly describe the current knowledge of innate immunity and how this can be utilized to prime tumors for a better response to immune checkpoint inhibitors. Comments on compounds in development and ongoing clinical trials will be provided.

Download Full-text

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

Immunotherapy ◽

10.2217/imt-2021-0119 ◽

2021 ◽

Author(s):

Ahmad A Tarhini ◽

Ila Joshi ◽

Fiona Garner

Keyword(s):

Immune Responses ◽

Metastatic Melanoma ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Unmet Needs ◽

Checkpoint Inhibitors ◽

Advanced Melanoma ◽

Clinical Activity ◽

Gm Csf ◽

Adaptive Immune

The use of immune checkpoint inhibitors in patients with metastatic melanoma generates clinical benefit, including improved survival. Yet disease resistance and immune-related adverse events persist as unmet needs. Sargramostim, a yeast-derived recombinant human GM-CSF, has shown clinical activity against diverse solid tumors, including metastatic melanoma. Here we review the use of sargramostim for treatment of advanced melanoma. Potential sargramostim applications in melanoma draw on the unique ability of GM-CSF to link innate and adaptive immune responses. We review preclinical and translational data describing the mechanism of action of sargramostim and synergy with immune checkpoint inhibitors to enhance efficacy and reduce treatment-related toxicity.

Download Full-text

Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

Frontiers in Cardiovascular Medicine ◽

10.3389/fcvm.2021.812702 ◽

2022 ◽

Vol 8 ◽

Author(s):

Felix Sebastian Nettersheim ◽

Felix Simon Ruben Picard ◽

Friedrich Felix Hoyer ◽

Holger Winkels

Keyword(s):

Immune Responses ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Preclinical Studies ◽

Adaptive Immune Responses ◽

Adaptive Immune ◽

Inhibitory Molecules ◽

Cancer Immunotherapies ◽

Two Sides

The development and clinical approval of immunotherapies has revolutionized cancer therapy. Although the role of adaptive immunity in atherogenesis is now well-established and several immunomodulatory strategies have proven beneficial in preclinical studies, anti-atherosclerotic immunotherapies available for clinical application are not available. Considering that adaptive immune responses are critically involved in both carcinogenesis and atherogenesis, immunotherapeutic approaches for the treatment of cancer and atherosclerosis may exert undesirable but also desirable side effects on the other condition, respectively. For example, the high antineoplastic efficacy of immune checkpoint inhibitors, which enhance effector immune responses against tumor cells by blocking co-inhibitory molecules, was recently shown to be constrained by substantial proatherogenic properties. In this review, we outline the specific role of immune responses in the development of cancer and atherosclerosis. Furthermore, we delineate how current cancer immunotherapies affect atherogenesis and discuss whether anti-atherosclerotic immunotherapies may similarly have an impact on carcinogenesis.

Download Full-text

CD8+lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury

Experimental Dermatology ◽

10.1111/exd.13436 ◽

2017 ◽

Vol 27 (1) ◽

pp. 71-79 ◽

Cited By ~ 2

Author(s):

Rituparna Chakraborty ◽

Janin Chandra ◽

Shuai Cui ◽

Lynn Tolley ◽

Matthew A. Cooper ◽

...

Keyword(s):

Dendritic Cells ◽

Immune Responses ◽

Inflammasome Activation ◽

Adaptive Immune Responses ◽

Skin Injury ◽

Adaptive Immune

Download Full-text

Dendritic Cells in Innate and Adaptive Immune Responses against Influenza Virus

Viruses ◽

10.3390/v1031022 ◽

2009 ◽

Vol 1 (3) ◽

pp. 1022-1034 ◽

Cited By ~ 12

Author(s):

Artur Summerfield ◽

Kenneth McCullough

Keyword(s):

Dendritic Cells ◽

Influenza Virus ◽

Immune Responses ◽

Adaptive Immune Responses ◽

Adaptive Immune

Download Full-text

Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach

Microorganisms ◽

10.3390/microorganisms7100402 ◽

2019 ◽

Vol 7 (10) ◽

pp. 402

Author(s):

Titus Abiola Olukitibi ◽

Zhujun Ao ◽

Mona Mahmoudi ◽

Gary A. Kobinger ◽

Xiaojian Yao

Keyword(s):

Dendritic Cells ◽

Immune Responses ◽

Ebola Virus ◽

Vaccine Development ◽

Adaptive Immune Responses ◽

Adaptive Immune ◽

Immunological Approach ◽

Vaccine Approach ◽

Acquired Immune Responses ◽

Diverse Virus

In the prevention of epidemic and pandemic viral infection, the use of the antiviral vaccine has been the most successful biotechnological and biomedical approach. In recent times, vaccine development studies have focused on recruiting and targeting immunogens to dendritic cells (DCs) and macrophages to induce innate and adaptive immune responses. Interestingly, Ebola virus (EBOV) glycoprotein (GP) has a strong binding affinity with DCs and macrophages. Shreds of evidence have also shown that the interaction between EBOV GP with DCs and macrophages leads to massive recruitment of DCs and macrophages capable of regulating innate and adaptive immune responses. Therefore, studies for the development of vaccine can utilize the affinity between EBOV GP and DCs/macrophages as a novel immunological approach to induce both innate and acquired immune responses. In this review, we will discuss the unique features of EBOV GP to target the DC, and its potential to elicit strong immune responses while targeting DCs/macrophages. This review hopes to suggest and stimulate thoughts of developing a stronger and effective DC-targeting vaccine for diverse virus infection using EBOV GP.

Download Full-text

Toxic adjuvants alter the function and phenotype of dendritic cells to initiate adaptive immune responses induced by oralHelicobacter pylorivaccines

Helicobacter ◽

10.1111/hel.12536 ◽

2018 ◽

Vol 23 (6) ◽

Cited By ~ 6

Author(s):

Shuanghui Luo ◽

Wei Liu ◽

Zhiqin Zeng ◽

Feng Ye ◽

Chupeng Hu ◽

...

Keyword(s):

Dendritic Cells ◽

Immune Responses ◽

Adaptive Immune Responses ◽

Adaptive Immune

Download Full-text

Crosstalk between Dendritic Cells and Immune Modulatory Agents against Sepsis

Genes ◽

10.3390/genes11030323 ◽

2020 ◽

Vol 11 (3) ◽

pp. 323 ◽

Cited By ~ 1

Author(s):

Guoying Wang ◽

Xianghui Li ◽

Lei Zhang ◽

Abualgasim Elgaili Abdalla ◽

Tieshan Teng ◽

...

Keyword(s):

Immune Response ◽

Dendritic Cells ◽

Immune Responses ◽

Critical Role ◽

Innate Immune ◽

Adaptive Immune Responses ◽

Adaptive Immune ◽

Th2 Responses ◽

Novel Strategy

Dendritic cells (DCs) play a critical role in the immune system which sense pathogens and present their antigens to prime the adaptive immune responses. As the progression of sepsis occurs, DCs are capable of orchestrating the aberrant innate immune response by sustaining the Th1/Th2 responses that are essential for host survival. Hence, an in-depth understanding of the characteristics of DCs would have a beneficial effect in overcoming the obstacle occurring in sepsis. This paper focuses on the role of DCs in the progression of sepsis and we also discuss the reverse sepsis-induced immunosuppression through manipulating the DC function. In addition, we highlight some potent immunotherapies that could be used as a novel strategy in the early treatment of sepsis.

Download Full-text